ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512288-29-00

Enrollment

Registered

2024-10-03

Start date

2023-04-11

Completion date

Unknown

Last updated

2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

Brief summary

Objective response rate (ORR) at 12 weeks according to RECIST v1.1

Detailed description

• Duration of Response (DoR) • Progression-free survival (PFS) according to RECIST v1.1 • Disease control rate (DCR) according to RECIST v1.1 • Overall survival (OS) • Safety and tolerability (CTCAE v5.0)

Interventions

DRUGJNJ-61186372

DRUGJNJ-73841937

DRUGZirabev 25 mg/ml concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR) at 12 weeks according to RECIST v1.1	—

Secondary

Measure	Time frame
• Duration of Response (DoR) • Progression-free survival (PFS) according to RECIST v1.1 • Disease control rate (DCR) according to RECIST v1.1 • Overall survival (OS) • Safety and tolerability (CTCAE v5.0)	—

Countries

France, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026